Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Response Genetics, a developer of clinical diagnostic tests for cancer, has announced an agreement with NeoGenomics Laboratories, a clinical laboratory service provider of oncology focused genetic diagnostic tests, and the formation of its own sales team, as part of its sales strategy to offer its ResponseDX: Colon and ResponseDX: Lung tests nationwide.
Subscribe to our email newsletter
ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to help physicians with therapeutic treatment decisions for patients with non-small cell lung cancer and colorectal cancer.
In addition to Response Genetics offering its ResponseDX tests through its own newly formed specialized sales team, and under the terms of the agreement, NeoGenomics will be the exclusive national clinical reference laboratory authorized to offer Response Genetics’s proprietary tests through their own proven national sales force. All tests will be performed through Response Genetics’s Clinical Laboratory Improvement Amendment-certified laboratory.
Robert Gasparini, president and chief scientific officer of NeoGenomics, said: “We could not be more pleased than to have Response Genetics as a partner in this endeavor. We believe this combination of two leaders in molecular diagnostics will allow us to establish new accounts, differentiate our services, and increase our footprint in the expanding field of molecular cancer genetics.”